Experimental Back Pain Treatment Moves Toward Phase 3
New data on a targeted antibiotic therapy offers hope for patients with specific forms of chronic lumbar back pain.
Updated on Oct. 22, 2026 in Diseases — General
Live Poll
Do you believe pharmaceutical treatments adequately address the root causes of chronic back pain?
Persica Pharmaceuticals presented a new exposure-response analysis for its experimental back pain therapy, PP353, at the International Society of Pain & Neuroscience Annual Conference. The drug, which targets a specific subset of chronic back pain patients, is slated to move into registrational Phase 3 trials.
Why it matters
The analysis aims to clarify previous inconsistent outcomes in antibiotic research for vertebrogenic lumbar back pain. For the approximately 10 million patients in the US and Europe with this condition, this research helps define the therapeutic requirements needed for effective treatment.
This exposure-response analysis evaluated existing clinical data to correlate intradiscal antibiotic exposure with outcomes for patients with Modic changes. While the analysis informs future study design, it remains a preliminary assessment of how localized antibiotic delivery impacts this pain type.
The players
Persica Pharmaceuticals
A London-based developer focused on non-opioid, intradiscal therapies for chronic back pain.
International Society of Pain & Neuroscience
A global organization that hosts annual conferences for researchers to share findings on pain mechanisms and treatments.
The details
PP353 is an experimental, non-opioid intradiscal therapy containing the antibiotic linezolid. It uses a thermosensitive vehicle that increases in viscosity upon injection, allowing the medication to remain at the site. The treatment protocol involves two administrations spaced four days apart to maintain the necessary local antibiotic exposure.
Timeline
February 2026: Phase 1b trial of PP353 published in eClinicalMedicine.
October 22, 2026: Exposure-response analysis presented at the ISPN Annual Conference.
Health Landscape
The study of intradiscal antibiotics marks a departure from traditional systemic pain management by targeting the potential underlying localized inflammation associated with Modic changes. This approach is currently being evaluated against long-standing reliance on opioids and surgical interventions for spinal pain.
Vertebrogenic lumbar back pain is a specific diagnosis characterized by changes often visible on imaging, which may be worth discussing with a spine specialist. While PP353 is not yet available, clinical trials remain an important avenue to watch for patients seeking non-opioid treatment options.
The takeaway
Understanding whether your back pain is associated with Modic changes is a helpful step in clarifying your diagnostic profile with your care team. Continue to track new, evidence-based non-opioid developments for spinal health as they move through the clinical trial process.
Further reading
For more information on the current state of chronic back pain treatment, visit Diseases — General.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe pharmaceutical treatments adequately address the root causes of chronic back pain?
